800-551-0488

Lab results are too important to go anywhere else

Beaumont Laboratory

Saccharomyces Cerevisiae Ab, IgA

ASCA, Anti saccharomyces cerevisiae Antibody, Saccharomyces cerevisiae IgA Antibodies, Saccharomyces cerevisiae Antibody, IgA, Serum, Saccharomyces cerevisiae Antibodies, IgA, MAYO: AASCA, EPIC: LAB6645, SOFT: XSACA

Specimen Collection Criteria

Collect (preferred specimen): One plain Red-top tube.
Also acceptable: One Gold-top SST tube.

Physician Office/Drawsite Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to plastic transport tube and refrigerate (2-8°C or 36-46°F).

Preparation for Courier Transport

Transport: 0.5 mL serum, refrigerated (2-8°C or 36-46°F). (Min: 0.4 mL)

Rejection Criteria

  • Specimens that are grossly lipemic.
  • Specimens that are grossly hemolyzed.
  • Specimens not collected and processed as indicated.

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): Unacceptable
Refrigerated (2-8°C or 36-46°F): 21 days
Frozen (-20°C/-4°F or below): 21 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Sendout Laboratory with any questions.

Laboratory

Sent to Mayo Medical Laboratory, Rochester, MN.

Performed

Monday - Friday
Results available in 2-4 days.

Reference Range

Negative: 0.0-20.0 U.
Equivocal: 20.1-24.9 U.
Weakly positive: 25.0-34.9 U.
Positive: Greater than or equal to 35.0 U.

Test Methodology

Enzyme-Linked Immunosorbent Assay (ELISA).

Clinical Utility

This test aids in differentiating Crohn's disease from ulcerative colitis.

Crohn's disease and ulcerative colitis are two types of inflammatory bowel disease. Crohn's disease usually affects the small intestine, however it can affect any part of the digestive tract and may be segmental. Ulcerative colitis causes inflammatory changes and ulcerations in the colon and rectum. Signs and symptoms of Crohn's disease and ulcerative colitis can be similar and diagnosis may be difficult.

Recent studies have shown that antisaccaromyces cerevisiae antibodies (ASCA) are more likely to occur in Crohn's disease than in ulcerative colitis or healthy controls. One study found the presence of both IgG and IgA ASCA was 100% specific for Crohn's disease, however not all patients with Crohn's disease have these antibodies.

A large proportion (approximately 70%) of patients with ulcerative colitis have been found to be positive for P-ANCA (perinuclear antineutrophilic cytoplasmic antibodies). Use of both ASCA and ANCA could assist in differentiating ulcerative colitis from Crohn's disease. The following table summarizes likelihood of positivity in ASCA and ANCA testing in Crohn's disease and ulcerative colitis.

  ASCA IgG ASCA IgA P-ANCA
Crohn's disease 80% positive 35% positive Less than 20% positive
Ulcerative colitis 20% positive Less than 1% positive 70% positive

CPT Code

86671.

Test Codes

MAYO: AASCA, EPIC: LAB6645, SOFT: XSACA

Last Updated

07/16/2017

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.